Welcome to our dedicated page for Neumora Therapeutics news (Ticker: NMRA), a resource for investors and traders seeking the latest updates and insights on Neumora Therapeutics stock.
Neumora Therapeutics, Inc. (Nasdaq: NMRA) is a clinical-stage biopharmaceutical company pioneering a new approach to treating brain diseases. Founded to address the global brain disease crisis, Neumora focuses on developing innovative therapies for neuropsychiatric and neurodegenerative disorders, areas with significant unmet medical needs.
Neumora's therapeutic pipeline comprises seven clinical and preclinical neuroscience programs targeting novel mechanisms of action. These programs aim to treat a broad range of underserved conditions, with ongoing projects for major depressive disorder (MDD), bipolar depression (BPD), Alzheimer's disease agitation, and schizophrenia, among others.
One of Neumora's leading candidates is Navacaprant (NMRA-140), a selective kappa opioid receptor (KOR) antagonist. Currently in Phase 3 clinical trials under the KOASTAL program, Navacaprant is being evaluated for its efficacy as a monotherapy for MDD. The company aims to extend its application to other neuropsychiatric disorders, including BPD.
Another notable program involves NMRA-266, a positive allosteric modulator of the M4 muscarinic receptor, being developed for schizophrenia. Despite a recent clinical hold due to safety findings in preclinical studies, Neumora is collaborating with the FDA to resolve these issues and is progressing with additional compounds within its M4 franchise.
Neumora's financial condition remains robust, with $519.5 million in cash and marketable securities as of September 30, 2023, projected to fund operations into 2026. The company reported a net loss of $53.0 million for Q3 2023, reflecting increased R&D expenses due to the advancement of clinical programs.
Recent achievements include a successful initial public offering and multiple clinical milestones. The company is on track to achieve significant milestones in 2024 and 2025, including data readouts from its Phase 3 navacaprant program and Phase 1 data from NMRA-266.
Neumora's mission is to redefine neuroscience drug development by leveraging an integrated suite of translational, clinical, and computational tools to create precision medicine approaches. This innovative strategy aims to improve treatment outcomes and quality of life for patients suffering from debilitating brain diseases.
FAQ
What is the current stock price of Neumora Therapeutics (NMRA)?
What is the market cap of Neumora Therapeutics (NMRA)?
What is Neumora Therapeutics, Inc.?
What are Neumora's key programs?
What is Navacaprant (NMRA-140)?
What is NMRA-266?
How is Neumora funded?
What are Neumora's recent achievements?
What is Neumora's mission?
What financial results did Neumora report for Q3 2023?
What milestones does Neumora expect in 2024 and 2025?
What are the main therapeutic areas Neumora targets?
